[Takayasu's arteritis and atherosclerosis]

A Hatri1, R Guermaz2, J-P Laroche3

  • 1Unité de médecine vasculaire, clinique d'Elbiar, Alger, Algérie.

Insights

Takayasu's arteritis and rheumatoid arthritis patients exhibit accelerated atherosclerosis, even with low cardiovascular risk. Inflammation plays a key role, necessitating proactive cardiovascular prevention strategies for Takayasu's disease.

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Vascular Biology

Background:

  • Chronic inflammatory diseases like SLE and RA increase cardiovascular morbidity and mortality due to premature atherosclerosis.
  • Atherosclerosis is linked to chronic systemic inflammation, independent of traditional cardiovascular risk factors.
  • Large artery vasculitis, such as Takayasu's disease, involves both systemic and local vascular inflammation.

Purpose of the Study:

  • To investigate the prevalence and characteristics of atherosclerosis in patients with Takayasu's arteritis compared to rheumatoid arthritis and controls.
  • To assess the role of inflammation in the development of premature atherosclerosis in these patient groups.

Main Methods:

  • A prospective case-control study involving 64 Takayasu's arteritis patients, 50 RA patients, and a control group.
  • Assessment of classic cardiovascular risk factors and calculation of risk using the Framingham equation.
  • Measurement of carotid intima-media thickness (IMT) and evaluation for carotid, aortic, and femoral atheroma.

Main Results:

  • No significant difference in calculated cardiovascular risk was observed between Takayasu's, RA, and control groups.
  • Subclinical atherosclerosis (IMT > 0.70mm and/or atheroma plaque) was significantly higher in Takayasu's patients (87%) and RA patients (76%) compared to controls (48%).
  • Carotid IMT was significantly higher in Takayasu's patients (0.91mm) compared to RA patients (0.76mm) and controls (0.71mm).

Conclusions:

  • Atherosclerosis in Takayasu's disease is accelerated and premature, occurring in younger individuals with low cardiovascular risk.
  • Systemic and local inflammation in Takayasu's arteritis likely drives accelerated atherosclerosis.
  • An active cardiovascular prevention strategy is recommended for patients with Takayasu's disease.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...